Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Cancer Gene Therapy Market Growth Potential: How Will Market Size Change Through 2030?
The market for cancer gene therapy has experienced substantial expansion recently, projected to increase from $4.21 billion in 2025 to $4.9 billion in 2026, reflecting a compound annual growth rate (CAGR) of 16.4%. This historical growth trajectory can be attributed to several key factors, including significant strides in molecular oncology research, a broader scope of clinical trials focusing on gene therapy, heightened investments in biopharmaceutical research and development, the successful regulatory clearance of initial gene therapies, and enhancements in the manufacturing processes for therapeutic vectors.
Within the realm of cancer gene therapy, a significant expansion is anticipated in the upcoming years, projecting a market valuation of $8.9 billion by 2030, driven by a compound annual growth rate of 16.1%. This projected expansion is underpinned by several key factors: a heightened demand for customized cancer interventions, escalating investments directed towards the production capabilities for cell and gene therapies, advancements in viral vector technologies for the next generation, a growing emphasis on multi-agent oncology treatments, and the increasing integration of precise oncology methodologies. Key developments shaping this market during the forecast period encompass the ongoing creation of specialized gene therapy platforms, a greater embrace of CAR-T and TCR therapies, heightened attention on refining viral vector performance, the broadening availability of individualized cancer gene treatments, and improved incorporation of biomarker-driven treatment selection strategies.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27233&type=smp
Cancer Gene Therapy Market Industry Drivers: What Is Driving Revenue Growth?
The escalating prevalence of cancer is anticipated to serve as a significant catalyst for the expansion of the cancer gene therapy sector. Cancer, a condition defined by the rampant proliferation of aberrant cells capable of infiltrating and disseminating throughout the body, originates in diverse tissues and organs and is categorized according to its cellular or tissue origin. Factors contributing to the rising tide of cancer diagnoses include extended lifespans, as the likelihood of developing the disease escalates with advancing age. Cancer gene therapy endeavors to combat this disease by altering or substituting defective genes to halt the proliferation of cancerous cells or to bolster the body’s immune defenses against them. Illustratively, Macmillan Cancer Support, a UK entity, disclosed in August 2024 that upwards of three million individuals in the United Kingdom are currently contending with cancer, a number poised to rise to 3.5 million by 2025, 4 million by 2030, and a substantial 5.3 million by 2040, clearly underscoring the upward trend in cancer incidence as the primary driver for the cancer gene therapy market’s growth trajectory.
Cancer Gene Therapy Market Segmentation Trends And Revenue Drivers
The cancer gene therapy market covered in this report is segmented –
1) By Therapy: Gene Induced Immunotherapy, Oncolytic Virotherapy, Gene Transfer
2) By Indication: Large B-Cell Lymphoma, Multiple Myeloma, Acute Lymphoblastic Leukemia (ALL), Melanoma (lesions), Other Indications
3) By Vector Type: Lentivirus, RetroVirus And Gamma RetroVirus, Adeno-Associated Virus (AAV), Modified Herpes Simplex Virus, Adenovirus, Other Vector Types
4) By End-User: Hospitals, Research Institutes, Biopharma Companies, Cell Therapy Manufacturing Centers, Other End Users
Subsegments:
1) By Gene Induced Immunotherapy: CAR-T Cell Therapy, TCR (T-Cell Receptor) Therapy, Tumor-Infiltrating Lymphocyte (TIL) Therapy, Dendritic Cell-Based Gene Therapy, NK Cell Gene Therapy
2) By Oncolytic Virotherapy: Adenoviruses, Herpes Simplex Virus (HSV), Reovirus, Vaccinia Virus, Newcastle Disease Virus (NDV)
3) By Gene Transfer: Viral Gene Transfer, Non-Viral Gene Transfer
#Cancer Gene Therapy Market Growth Trends: What Is Influencing The Future Outlook?
Leading entities within the cancer gene therapy sector are dedicating their efforts to the creation of cutting-edge treatments, exemplified by CAR-T cell therapy, with the objective of augmenting treatment accuracy, elevating patient results, and more precisely targeting neoplastic cells while concurrently reducing harm to non-cancerous tissues. CAR-T therapy represents a sophisticated form of immunotherapy involving the genetic modification of an individual’s own immune cells to improve their capacity for identifying and eradicating malignant cells through the introduction of specific receptors. Illustratively, in April of 2024, a biotechnology firm situated in India, known as ImmunoACT, introduced NexCAR19 (actalycabtagene autoleucel), a CAR-T cell therapy for oncological conditions that originated entirely within the country. NexCAR19, engineered with the specific aim of managing B-cell lymphomas and leukemias, functions by reconfiguring the patient’s T cells to recognize and eliminate cancerous cells. This treatment, grounded in sophisticated chimeric antigen receptor (CAR) technology, is produced domestically, thereby rendering it more cost-effective and readily available compared to therapies imported from abroad. This introduction signifies a pivotal moment for India’s engagement in the worldwide arena of cancer gene therapy, underscoring substantial advancements in indigenous innovation and the provision of customized cancer care.
#Cancer Gene Therapy Market Industry Leaders: Which Organizations Are Driving Competition?
Major companies operating in the cancer gene therapy market are Bristol Myers Company, Novartis AG, GSK plc., Gilead Sciences Inc., Amgen Inc., Orchard Therapeutics Plc, AGC Biologics, Adaptimmune Limited, Sibiono, Elevate Bio Inc., Bluebird Bio Inc., Uniqure N.V., Shanghai Sunway Biotech Co. Ltd., Anges Inc., Gensight Biologics, Genelux Corporation, Cellectis, Abeona Therapeutics Inc., Kite Pharma Inc., Janssen Biotech Inc., Mustang Bio Inc., Intellia Therapeutics Inc., CRISPR Therapeutics AG, Caribou Biosciences Inc.
Access The Complete Cancer Gene Therapy Market Report:
https://www.thebusinessresearchcompany.com/report/cancer-gene-therapy-global-market-report
Cancer Gene Therapy Market Regional Analysis: Which Region Leads By Revenue?
North Americawas the largest region in the cancer gene therapy market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the cancer gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model